Pfizer (PFE) Deferred Taxes (2009 - 2026)
Pfizer (PFE) reported Deferred Taxes of -$12.0 million for Q1 2026, up 98.19% year-over-year from -$6.1 million in Q1 2025, and up 97.23% quarter-over-quarter from -$433.0 million in Q4 2025.
Pfizer (PFE) Deferred Taxes (2009 - 2026) Analysis & Trends
Pfizer (PFE) has 18 years of Deferred Taxes data on file, last reported at -$12.0 million in Q1 2026.
- Deferred Taxes for Q1 2026 came in at -$12.0 million, up 98.19% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.5 billion (up 58.75% YoY), and the FY2025 annual result was -$2.1 billion, down 1.47% from the prior year.
- Deferred Taxes improved to -$12.0 million in Q1 2026 per PFE's latest filing, from -$433.0 million in the prior quarter.
- Over five years, Deferred Taxes peaked at -$12.0 million in Q1 2026 and troughed at -$3.4 billion in Q4 2022.
- A 5-year average of -$1.0 billion and a median of -$765.0 million in 2025 frame the typical range for Deferred Taxes.
- The sharpest annual moves came in 2022 and 2026: Deferred Taxes sank 1627.27% in 2022, then jumped 98.19% in 2026.
- A 5-year view of Deferred Taxes shows it stood at -$3.4 billion in 2022, then soared by 45.34% to -$1.9 billion in 2023, then climbed by 8.18% to -$1.7 billion in 2024, then jumped by 74.62% to -$433.0 million in 2025, then jumped by 97.23% to -$12.0 million in 2026.
- Business Quant data shows PFE's Deferred Taxes at -$12.0 million in Q1 2026, -$433.0 million in Q4 2025, and -$765.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 1.48 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 159.00 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 137.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -315.00 Mn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | -176.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 179.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -12.00 Mn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 161.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | -12.00 Mn |
| Dec 31, 2025 | -433.00 Mn |
| Sep 28, 2025 | -765.00 Mn |
| Jun 29, 2025 | -272.00 Mn |
| Mar 30, 2025 | -663.00 Mn |
| Sep 29, 2024 | -1.71 Bn |
| Jun 30, 2024 | -783.00 Mn |
| Mar 31, 2024 | -441.00 Mn |
| Dec 31, 2023 | -1.86 Bn |
| Oct 1, 2023 | -113.00 Mn |
| Jul 2, 2023 | -873.00 Mn |
| Apr 2, 2023 | -598.00 Mn |
| Oct 2, 2022 | -3.40 Bn |
| Jul 3, 2022 | -1.14 Bn |
| Apr 3, 2022 | -2.32 Bn |
| Oct 3, 2021 | -3.61 Bn |
| Jul 4, 2021 | -66.00 Mn |
| Apr 4, 2021 | 203.00 Mn |
| Sep 27, 2020 | -735.00 Mn |
| Jun 28, 2020 | -49.00 Mn |